GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 3,728 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $76.75, for a total transaction of $286,124.00. Following the completion of the transaction, the chief financial officer now directly owns 28,200 shares of the company's stock, valued at $2,164,350. This trade represents a 11.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Kevin Feeley also recently made the following trade(s):
- On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $86,832.69.
- On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The stock was sold at an average price of $78.39, for a total transaction of $20,616.57.
- On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total value of $886,521.44.
- On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $18,248.40.
GeneDx Price Performance
Shares of WGS stock opened at $76.93 on Thursday. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -24.74 and a beta of 2.03. GeneDx Holdings Corp. has a 12 month low of $1.76 and a 12 month high of $89.11. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a 50-day moving average price of $71.70 and a 200 day moving average price of $46.76.
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days.
It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year.
This is where fortunes are made – often LITERALLY overnight.
>> Register for the Workshop Now
GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company had revenue of $76.90 million during the quarter, compared to analysts' expectations of $64.98 million. During the same quarter in the previous year, the company earned ($0.82) EPS. GeneDx's revenue was up 44.3% on a year-over-year basis. Research analysts expect that GeneDx Holdings Corp. will post -0.24 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Franklin Resources Inc. acquired a new position in shares of GeneDx during the 3rd quarter worth about $301,000. Tidal Investments LLC acquired a new position in GeneDx during the third quarter valued at approximately $514,000. Barclays PLC increased its stake in GeneDx by 346.3% in the third quarter. Barclays PLC now owns 18,921 shares of the company's stock valued at $803,000 after purchasing an additional 14,681 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of GeneDx by 8.7% during the third quarter. Geode Capital Management LLC now owns 377,631 shares of the company's stock worth $16,030,000 after purchasing an additional 30,379 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of GeneDx by 18.3% in the 3rd quarter. State Street Corp now owns 314,914 shares of the company's stock valued at $13,365,000 after buying an additional 48,735 shares during the period. Institutional investors and hedge funds own 61.72% of the company's stock.
Analyst Ratings Changes
A number of analysts have recently weighed in on the company. Wells Fargo & Company raised their target price on GeneDx from $34.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 30th. Craig Hallum raised their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group boosted their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $59.33.
Read Our Latest Research Report on GeneDx
GeneDx Company Profile
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
